National Pension Service Sells 2,208 Shares of United Therapeutics Corporation $UTHR

Key Points

• National Pension Service cut its United Therapeutics stake by 6.7%, selling 2,208 shares during the second quarter and retaining 30,885 shares valued at approximately $16.7 million. Institutional investors collectively own 94.08% of the company.
• Analysts remain broadly positive on UTHR, with 11 Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $646, despite some recent target reductions.
• United Therapeutics exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus, but revenue fell 1.9% year over year to $783.3 million. Insiders have sold roughly 384,075 shares worth $202.4 million over the past 90 days.

National Pension Service reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 6.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,885 shares of the biotechnology company's stock after selling 2,208 shares during the quarter. National Pension Service owned about 0.07% of United Therapeutics worth $16,734,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Toth Financial Advisory Corp increased its position in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock valued at $27,000 after buying an additional 48 shares in the last quarter. Fiduciary Financial Advisors bought a new stake in United Therapeutics in the second quarter worth $30,000. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on UTHR shares. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. TD Cowen restated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Finally, Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $646.00.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $482.03, for a total value of $4,000,849.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $21,774,259.16. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $502.35, for a total transaction of $4,772,325.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $162,983,941.05. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 384,075 shares of company stock valued at $202,367,758. Corporate insiders own 8.60% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $497.11 on Friday. The stock has a market capitalization of $21.32 billion, a price-to-earnings ratio of 17.79, a PEG ratio of 2.48 and a beta of 0.56. United Therapeutics Corporation has a 1-year low of $396.12 and a 1-year high of $609.35. The business's fifty day moving average price is $520.91 and its 200-day moving average price is $540.30.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. During the same quarter in the prior year, the business earned $6.41 earnings per share. United Therapeutics's revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.21 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.